Dyadic International Inc. ( (DYAI) ) has released its Q3 earnings. Here is a breakdown of the information Dyadic International Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Dyadic Applied BioSolutions, formerly known as Dyadic International Inc., is a global biotechnology company that specializes in producing precision-engineered, animal-free proteins and enzymes for various commercial applications across life sciences, food and nutrition, and bio-industrial markets. The company leverages its proprietary microbial platforms to offer scalable and cost-effective solutions.
In its third-quarter 2025 earnings report, Dyadic announced a strategic pivot from a research and development focus to a commercial focus, rebranding itself as Dyadic Applied BioSolutions. The company highlighted significant achievements, including advancing recombinant protein programs, securing a CRISPR license, and strengthening its financial position through an equity offering.
Key financial metrics revealed a decrease in total revenue to $1.165 million from $1.958 million in the same period the previous year, primarily due to a reduction in research and development revenue and license and milestone revenue. However, the company saw an increase in grant revenue from collaborations with the Gates Foundation and CEPI. Despite a rise in research and development and general administrative expenses, Dyadic strengthened its cash position to $10.4 million as of September 30, 2025.
Strategically, Dyadic made significant strides by securing a CRISPR license, enhancing its genetic engineering capabilities, and expanding its commercial efforts in Asia. The company also validated its C1 platform for vaccine antigen production and continued to develop non-animal derived products for various applications, including cell culture media and nutritional markets.
Looking ahead, Dyadic’s management remains optimistic about the company’s potential for sustainable revenue growth and long-term value creation, supported by its strategic transformation and enhanced capabilities in the biotechnology sector.